Sun Pharmaceutical acquires Organon for $11.75 billion in all-cash deal

13 articles · Updated · CNBC · Apr 27

Sun Pharma will pay $14 per Organon share, valuing the U.S.-based company at $11.75 billion including debt, and its shares rose 5%.
The acquisition boosts Sun Pharma into the top 25 global pharmaceutical firms, with combined revenue reaching $12.4 billion and innovative medicines projected to contribute 27% of total sales.
Organon, spun off from Merck in 2021, specializes in women's health and biosimilars, selling over 70 products in 140 countries, and strengthens Sun Pharma's presence in key global markets.

How will Sun Pharma manage Organon's $8.6B debt while funding innovation in women's health?

Is Sun Pharma buying a strategic gem or catching a falling knife with its $11.75B Organon bet?

With Organon's recent scandals, can Sun Pharma's turnaround expertise avoid another complex integration like Ranbaxy?

Does this deal signal a new era of Indian pharma dominance or a risky overreach into Western markets?

Can a generics giant pivot to an innovator by acquiring a company with declining sales and massive debt?